The Light Chain Allosterically Enhances the Protease Activity of Murine Urokinase-Type Plasminogen Activator

被引:0
|
作者
Torres-Paris, Constanza [1 ]
Song, Harriet J. [1 ]
Engelberger, Felipe [2 ,3 ,4 ,5 ]
Ramirez-Sarmiento, Cesar A. [2 ,3 ,4 ,5 ]
Komives, Elizabeth A. [1 ]
机构
[1] Univ Calif San Diego, Dept Chem & Biochem, Mail Code 0309, La Jolla, CA 92161 USA
[2] Pontificia Univ Catolica Chile, Inst Biol & Med Engn, Sch Engn, Santiago 7820436, Chile
[3] Pontificia Univ Catolica Chile, Inst Biol & Med Engn, Sch Med, Santiago 7820436, Chile
[4] Pontificia Univ Catolica Chile, Inst Biol & Med Engn, Sch Biol Sci, Santiago 7820436, Chile
[5] Millennium Inst Integrat Biol iBio, ANID Millennium Sci Initiat Program, Santiago 8331150, Chile
关键词
CATALYTIC DOMAIN; A-CHAIN; CRYSTAL-STRUCTURE; SERINE-PROTEASE; EXCHANGE; DYNAMICS; BINDING; SUBSTITUTION; MUTATIONS; MECHANISM;
D O I
10.1021/acs.biochem.4c00071
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The active form of the murine urokinase-type plasminogen activator (muPA) is formed by a 27-residue disordered light chain connecting the amino-terminal fragment (ATF) with the serine protease domain. The two chains are tethered by a disulfide bond between C1(CT) in the disordered light chain and C122(CT) in the protease domain. Previous work showed that the presence of the disordered light chain affected the inhibition of the protease domain by antibodies. Here we show that the disordered light chain induced a 3.7-fold increase in k cat of the protease domain of muPA. In addition, hydrogen-deuterium exchange mass spectrometry (HDX-MS) and accelerated molecular dynamics (AMD) were performed to identify the interactions between the disordered light chain and the protease domain. HDX-MS revealed that the light chain is contacting the 110s, the turn between the beta 10- and beta 11-strand, and the beta 7-strand. A reduction in deuterium uptake was also observed in the activation loop, the 140s loop and the 220s loop, which forms the S1-specificty pocket where the substrate binds. These loops are further away from where the light chain seems to be interacting with the protease domain. Our results suggest that the light chain most likely increases the activity of muPA by allosterically favoring conformations in which the specificity pocket is formed. We propose a model by which the allostery would be transmitted through the beta-strands of the beta-barrels to the loops on the other side of the protease domain.
引用
收藏
页码:1434 / 1444
页数:11
相关论文
共 50 条
  • [21] Plasma clearance of urokinase-type plasminogen activator
    van der Kaaden, ME
    Rijken, DC
    van Berkel, TJC
    Kuiper, J
    [J]. FIBRINOLYSIS & PROTEOLYSIS, 1998, 12 (04): : 251 - 258
  • [22] Nuclear translocation of urokinase-type plasminogen activator
    Stepanova, V.
    Kuo, A.
    Higazi, A.
    Yarovoi, S.
    Bdeir, K.
    Cines, D.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 : 228 - 228
  • [23] Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 and-2 in hepatocellular carcinoma
    Zhou, L
    Hayashi, Y
    Itoh, T
    Wang, WP
    Rui, JA
    Itoh, H
    [J]. PATHOLOGY INTERNATIONAL, 2000, 50 (05) : 392 - 397
  • [24] Urokinase-type plasminogen activator, an endogenous antibiotic
    Jin, T
    Bokarewa, M
    Tarkowski, A
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (03): : 429 - 437
  • [25] Macromolecular inhibition of urokinase-type plasminogen activator
    Laboissière, MCA
    Yang, Q
    Craik, CS
    [J]. FASEB JOURNAL, 1997, 11 (09): : A1397 - A1397
  • [26] Nuclear translocation of urokinase-type plasminogen activator
    Stepanova, Victoria
    Lebedeva, Tatiana
    Kuo, Alice
    Yarovoi, Serge
    Tkachuk, Sergei
    Zaitsev, Sergei
    Bdeir, Khalil
    Durnler, Inna
    Marks, Michael S.
    Parfyonova, Yelena
    Tkachuk, Vsevolod A.
    Higazi, Abd Al-Roof
    Cines, Douglas B.
    [J]. BLOOD, 2008, 112 (01) : 100 - 110
  • [27] UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND MALIGNANCY
    DUFFY, MJ
    [J]. FIBRINOLYSIS, 1993, 7 (05) : 295 - 302
  • [28] Ras regulation of urokinase-type plasminogen activator
    Lengyel, E
    Ried, S
    Heiss, MM
    Jäger, C
    Schmitt, M
    Allgayer, H
    [J]. REGULATORS AND EFFECTORS OF SMALL GTPASES, PT G, 2001, 333 : 105 - 116
  • [29] Urokinase-type plasminogen activator inhibitors.
    Squires, N
    McGee, D
    Allen, D
    Hruzewicz, W
    Spencer, J
    Sprengeler, P
    Katz, B
    Luong, C
    Mackman, R
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2001, 221 : U51 - U51
  • [30] Urokinase-type plasminogen activator overexpression enhances the invasive capacity of endothelial cells
    Gualandris, A
    Conejo, TL
    Giunciuglio, D
    Albini, A
    Sabini, E
    Rusnati, M
    DellEra, P
    Presta, M
    [J]. MICROVASCULAR RESEARCH, 1997, 53 (03) : 254 - 260